Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-01-04
2011-01-04
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S186100, C424S215100, C424S232100, C435S005000, C435S007100, C435S235100
Reexamination Certificate
active
07862821
ABSTRACT:
The present invention relates to an immunogenic or vaccine composition to induce an immune response or protective immune response againstOrbiviruses, more specifically bluetongue virus (BTV) in an animal susceptible to BTV infection. The composition may include a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector may contain heterologous nucleic acid molecule(s), expresses in vivo in the animal BTV antigen, immunogen or epitope thereof, e.g., BTV VP2; BTV VP2 and VP5; BTV VP2 and VP5 and VP3 and/or VP7. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.AGACAGTGGTCAATTCCAATGGTACTGTTTGACGATAC
REFERENCES:
patent: 5830463 (1998-11-01), Duke et al.
patent: 6130066 (2000-10-01), Tartaglia et al.
patent: 2005/0255127 (2005-11-01), Loosmore et al.
patent: 2007/0141557 (2007-06-01), Raab et al.
patent: WO 2004/059556 (2004-07-01), None
Lobato et al. Veterinary Immunology and Immunopathology, 1997, vol. 59, pp. 293-309.
Taylor et al. Vaccine, 1995, vol. 13, No. 6, pp. 539-549.
Minke et al. Veterinary Research, 2004, vol. 35, pp. 425-443.
Harpin et al. Journal of General Virology, 1999, vol. 80, pp. 3137-3144.
Abaza et al. Journal of Protein Chemistry, 1992, vol. 11, No. 5, pp. 433-444.
Riffkin et al. Gene, 1995, vol. 167, pp. 279-283.
Martyn et al., “Expression of the outer capsid proteins VP2 and VP5 of bluetongue virus inSaccharomyces cereuisiae ,”Virus Research, vol. 33 No. 1, pp. 11-25 (Jul. 1994).
GenBank AAB70533., “outer capsid protein VP2 [Bluetongue virus],” Sep. 1997.
GenBank AAA42823, “capsid protein VP5 [Bluetongue virus],” Apr. 1993.
Roy Pet al., Vaccine, Butterworth Scientific. Guildford, GB, vol. 12, No. 9, Jan. 1, 1994, pp. 805-811.
Roy P et al. , Vaccine, Butterworth Scientific. Guildford, GB, vol. 10, No. 1, Jan. 1, 1992, pp. 28-32.
Anderson J et al., Journal of Virological Methods, Elsevier BV, NL, vol. 43, No. 2, Jul. 1, 1993, pp. 167-175.
Karaca K et al., Vaccine, Butterworth Scientific. Guildford, GB, vol. 23, No. 29, May 31, 2005, pp. 3808-3813.
Bradel-Tretheway B Get al., Journal of Virological Methods, Elsevier BV, NL, vol. 111, No. 2, Aug. 1, 2003, pp. 145-156.
Disbrow G L et al., Virology, Academic Press,Orlando, US, vol. 311, No. 1, Jun. 20, 2003, pp. 105-114.
Murray P K et al., Australian Veterinary Journal, Australian Veterinary Association, Brunswick, AU, vol. 73, No. 6, Jan. 1, 1996, pp. 207-210.
Aucouturier et al. Vaccine 19 (2001) 2666-2672 “Adjuvants designed for veterinary and human vaccines”.
Edelman R. et al. AIDS Rfsearch and Human Retroviruses vol. 8, No. 8, 1992 “An Update on Vaccine Adjuvants in Clinical Trial”.
McElrath, MJ. Seminars in Cancer Biology, vol. 6, 1995: pp. 375-385 Selection of potent immunological adjuvants for vaccine construction.
Willson, PJ et al. Tissue Reaction and Immunity in Swine Immunized withActinobacillus pleuropneumoniaeVaccines. Can J Vet Res 1995; 59: 299-305.
Boone JD et al., “Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 . . . ”, Vaccine. Jan. 8, 2007;25(4):672-8.
Verwwoerd DW et al., “Structure of the bluetongue virus capsid”, J Virol. Oct. 1972;10(4):783-94.
Roy P et al., “Recombinant virus vaccine for bluetongue disease in sheep”, J Virol. May 1990;64(5):1998-2003.
Hassan SS, et al., “Expression and functional characterization of bluetongue virus VP2 protein: role in cell entry”, J Virol. Dec. 1999;73(12):9832-42.
Perrin A et al., “Recombinant capripoxviruses expressing proteins of bluetongue virus: Evaluation of immune . . . ”,Vaccine 25 Jul. 2007 6774-6783.
Andrew M et al., “Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus”, Vet Immunol Immunopathol Aug. 1995 47(3-4) 311-22.
Lobato Z et al., “Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue”, Vet Immunol Immunopathol Nov. 1997 59(3-4) 293-309.
Huismans H et al., “Isolation of a Capsid Protein of Bluetongue Virus That Induces a Protective Immune Response in Sheep”, Virology Mar. 1987 157(1) 172-9.
Roy P, “Orbivirus Structure and Assembly”, Virology Feb. 1996 216(1) 1-11.
De Mattos C et al.,“Heterogeneity of the L2 gene of field isolates of bluetongue virus serotype 17 from the San Joaquin”, Virus Res Jan. 1994 31(1) 67-87.
Demaula C et al., “Changes in the outer capsid proteins of bluetongue virus serotype ten that abrogate neutralization . . . ”, Virus Research 67 Jan. 2000 59-66.
Jones L et al., “The non-structural proteins of bluetongue virus are a dominant source of cytotoxic T cell peptide determinants . . . ”, J. General Virology (1996), 77, 99. UK.
Hyatt A et al., “Localization of the non-structural protein NS3 in bluetongue virus-infected cells”, J. General Virology (1991), 72, 2263-2267. Printed in UK.
Roy P et al., “Evidence for genetic relationship between RNA and DNA viruses from the sequence homology of a putative polymerase gene of Bluetongue virus . . . ”, NAR 1988, 16(28).
Janardhana V et al., “The ovine cytotoxic T lymphocyte responses to bluetongue virus”, Res Vet Sci. Dec. 1999;67(3):213-21.
Wilson et al., “Molecular Evolution of Orbiviruses”, The British Library—“The World's Knowledge”, pp. 169-180.
Andrew M et al., “Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus”, Vet Immunol Immunopathol. Aug. 1995;47(3-4):311-22.
Cloete M et al., “Vaccinia virus expression of the VP7 protein of South African bluetongue virus serotype 4 . . . ”, Arch Virol. 1994;135(3-4):405-18.
Eaton BT et al., “A bluetongue serogroup-reactive epitope in the amino terminal half of the major core protein VP7 is accessible . . . ”, Virology. Feb. 1991;180(2):687-96.
Takamatsu H et al., “Identification of a bluetongue virus serotype 1-specific ovine helper T-cell determinant . . . ”, Virology. Jul. 1990;177(1):396-400.
Wade-Evans AM et al., “Expression of the outer capsid protein, VP2, from a full length cDNA clone of genome segment 2 . . . ”, Virus Res. Mar. 1990;15(3):213-29.
Roy et al., “Orbiviruses and their Replication”, Fields Virology, 3rd Edition, 1996, Chapter 56, pp. 1709-1734.
Identification of the Serotype-specific and Group-Specific antigens of Bluetongue Virus, Onderstepoort J. Vet Research, 1981, 48, 51-58.
Audonnet Jean Christophe Francis
Karaca Kemal
MacLachlan Nigel James
Yao Jiansheng
Chen Ruoying
Jarecki-Black Judy
Lucas Zachariah
Merial Limited
Merial Limited
LandOfFree
Recombinant vaccine against bluetongue virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant vaccine against bluetongue virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant vaccine against bluetongue virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2722530